Cephalon Boosts Cancer Pipeline With Acquisition Valued At Up to $525 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty biopharma has gained two promising oncology drugs through the acquisition of privately-held Gemin X
You may also be interested in...
Financings Of The Fortnight: Thiel Looks To Bridge The Pre-Venture Capital Funding Gap For Biotech
Plus news on recent financing activity by Alcresta, Alder Biopharmaceuticals, H.I.G Capital and Supernus Pharmaceuticals.
H.I.G. BioVentures Closes Second Fund Above Target, Team Upbeat
H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.
Cephalon, A Target Itself, To Acquire Remainder Of Australian ChemGenex
Cephalon Inc. announced March 29 that it has struck an agreement with the Australia-based biopharma ChemGenex Pharmaceuticals Ltd. to pay A$159 million ($US $163 million) for the piece of the company it doesn't already own